LENZ Therapeutics: Below Cash For A Reason
LENZ Therapeutics Inc LENZ
$3.92
▲ +5.24%
(+$0.20)
⬆️ Above Yest. High
🔥 High Short Interest
Open
$3.75
Prev Close
$3.72
Day Range
$3.66 – $4.00
52W Range
$3.60 – $50.40
Market Cap
$123.01M
Beta
2.24
EPS (TTM)
$-4.08
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-25 |
| Shares Out. | 31,350,000 |
| Website | lenz-tx.com/ ↗ |
| Phone | 18589257000 |
| Employees | 152 |
| Revenue | $5.5M |
| Gross Profit | $5.2M |
| Net Income | -$31.9M |
| Free Cash Flow | -$114.4M |
| Total Assets | $236.6M |
| Total Liabilities | $17.3M |
| Equity | $219.3M |
About LENZ Therapeutics Inc
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
LENZ Therapeutics Inc is a publicly traded company under the ticker symbol LENZ on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)